Globally,hepatocellular carcinoma(HCC)is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates.Unfortunately,many of these patients are diagnosed in the advanced stages when locoregio...Globally,hepatocellular carcinoma(HCC)is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates.Unfortunately,many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate.Before 2008,no effective drug treatments existed to prolong survival,until the breakthrough multi-tyrosine kinase inhibitor(TKI)sorafenib was developed.It remained the standard treatment option for advanced HCC for 10 years,with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results.In 2018,the REFLECT trial introduced another multi-TKI,lenvatinib,which has non-inferior overall survival compared with sorafenib.Thus,offering patients and their treating physicians two effective treatment options.Recently,immunotherapy-based drugs,such as atezolizumab and bevacizumab,have shown promising results in patients with unresectable HCC.This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC.We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination;when more data become available,this will likely make the choice between sorafenib and lenvatinib somewhat obsolete.展开更多
文摘Globally,hepatocellular carcinoma(HCC)is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates.Unfortunately,many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate.Before 2008,no effective drug treatments existed to prolong survival,until the breakthrough multi-tyrosine kinase inhibitor(TKI)sorafenib was developed.It remained the standard treatment option for advanced HCC for 10 years,with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results.In 2018,the REFLECT trial introduced another multi-TKI,lenvatinib,which has non-inferior overall survival compared with sorafenib.Thus,offering patients and their treating physicians two effective treatment options.Recently,immunotherapy-based drugs,such as atezolizumab and bevacizumab,have shown promising results in patients with unresectable HCC.This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC.We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination;when more data become available,this will likely make the choice between sorafenib and lenvatinib somewhat obsolete.
